The data and AI algorithms within companion apps can help HCPs provide a diagnosis quicker, allowing them to compare their ...
Beyond is the ability to scan important items, enemies, and allies into a comprehensive Scan Logbook to reveal ...
Microbiomes play a vital role in everything from human health to soil fertility and climate regulation. But studying these ...
Biotech stocks are emerging from a four-year slump. The SPDR S&P Biotech exchange-traded fund XBI, a proxy for the sector, is up 25% so far this year through Oct. 31, beating the S&P 500 SPX by 9 ...
Welcome to the Fierce Biotech Graveyard, our annual ritual remembering the biotechs we lost in 2025 and those on the brink. In this episode, Fierce Biotech’s Darren Incorvaia and Gabrielle Masson came ...
Few neighborhoods in Cambridge have seen their fortunes change as dramatically as Kendall Square. Kendall was once known for churning out soap and vulcanized rubber, then manufacturing electronics as ...
In September 2024, Akeso, a little-known Chinese biopharmaceutical company, announced that clinical trials had shown that its new drug could halt the progression of a type of lung cancer for nearly a ...
Something unusual is happening to biotech stocks: They’re going up. A drug-pricing deal between Pfizer and the White House and a spate of deals have sent the SPDR S&P Biotech exchange-traded fund up 9 ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Data collected for venture ...
A handful of biotech stocks are showing renewed strength, with big spikes in their Benzinga Edge Ranking’s Momentum scores over the past week alone. Top 3 Biotech Stocks With A Big Surge In Momentum ...
Wall Street is looking for new ways to park cash in healthcare names, and large-cap biotechs have begun to gain steam. Biotechs are typically smaller companies working on research and development to ...
‘Disheartening? Yes. Surprising? No.’ Report on the future of biotech in Mass. gives a grim outlook.
The industry group MassBio released its annual temperature check on the state’s biotech industry Tuesday, and the results are grim. Both public and private funding have plummeted as federal policy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback